NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint ...
Researchers at the Institut Pasteur and Inserm have developed a novel triple-therapy that reprograms how B cell cancers ...
DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology East ...
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell ...
Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory ...
Provectus Biopharmaceuticals, Inc. ('Provectus” or the 'Company”) (OTCQB: PVCT) today announced the publication of independent preclinical research by Aru Narendran, MD, PhD and colleagues at the ...
This new article publication from Acta Pharmaceutica Sinica B, discusses how single-cell RNA sequencing reveals that Shen-Bai-Jie-Du decoction retards colorectal tumorigenesis by regulating the ...
Hosted on MSN
B-Cell Acute Lymphoblastic Leukemia for Adults: Causes, Symptoms, Diagnosis and Treatment
By Shreoshree Chakrabarty: B-Cell Acute Lymphoblastic Leukemia (B-ALL) is a rare but aggressive form of leukemia that primarily impacts adults, unlike its more common pediatric counterpart. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback